HopeStage
Back to all studies
CompletedNCT00214877

Methylene blue for cognitive difficulties in bipolarity

About this title

Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

Read the official source — NCT00214877
Medication studyAges 18–65Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Halifax and 1 more locationSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2003
Recruitment status
Completed
Enrollment listed in the registry
40
Sponsor
Nova Scotia Health Authority
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT00214877
Official title
Show the full official title

Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Halifax · Hamilton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Nova Scotia Health Authority.

Did this study involve medication?

Yes. The study involved medication, including Methylene Blue.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies